Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
Authors:
Open Access
- 26 September 2023
- journal article
- review article
- Published by OAE Publishing Inc. in Microbiome Research Reports
- Vol. 2 (4) , 35
Abstract
Inflammatory bowel disease (IBD) is a complex heterogeneous disorder defined by recurring chronic inflammation of the gastrointestinal tract, attributed to a combination of factors including genetic susceptibility, altered immune response, a shift in microbial composition/microbial insults (infection/exposure), and environmental influences. Therapeutics generally used to treat IBD mainly focus on the immune response and include non-specific anti-inflammatory and immunosuppressive therapeutics and targeted therapeutics aimed at specific components of the immune system. Other therapies include exclusive enteral nutrition and emerging stem cell therapies. However, in recent years, scientists have begun to examine the interplay between these therapeutics and the gut microbiome, and we present this information here. Many of these therapeutics are associated with alterations to gut microbiome composition and functionality, often driving it toward a “healthier profile” and preclinical studies have revealed that such alterations can play an important role in therapeutic efficacy. The gut microbiome can also improve or hinder IBD therapeutic efficacy or generate undesirable metabolites. For certain IBD therapeutics, the microbiome composition, particularly before treatment, may serve as a biomarker of therapeutic efficacy. Utilising this information and manipulating the interactions between the gut microbiome and IBD therapeutics may enhance treatment outcomes in the future and bring about new opportunities for personalised, precision medicine.Keywords
This publication has 197 references indexed in Scilit:
- Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgensJournal of Lipid Research, 2013
- Review article: remission rates achievable by current therapies for inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2011
- Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivoGut, 2010
- Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled StudyAmerican Journal of Gastroenterology, 2010
- Substrate-driven gene expression in Roseburia inulinivorans : Importance of inducible enzymes in the utilization of inulin and starchProceedings of the National Academy of Sciences, 2010
- Towards New Antifolates Targeting Eukaryotic Opportunistic InfectionsEukaryotic Cell, 2009
- On the Action of Methotrexate and 6-Mercaptopurine on M. avium Subspecies paratuberculosisPLOS ONE, 2007
- Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditionsEuropean Journal of Clinical Pharmacology, 1992
- Cofactor requirements of steroid- 17-20-desmolase and 20α-hydroxysteroid dehydrogenase activities in cell extracts of Clostridium scindensThe Journal of Steroid Biochemistry and Molecular Biology, 1987
- Sulfasalazine-Induced Exacerbation of Ulcerative ColitisNew England Journal of Medicine, 1982